At 24 months' follow-up, the only phase 3 randomized clinical trial to directly compare functional and oncologic outcomes between robot-assisted laparoscopic prostatectomy and open radical retropubic ...

Prostate cancer is the most common malignant tumor in men, accounting for 29% of male neoplasm diagnoses in the United States alone. Radical prostatectomy remains the preferred treatment for localized ...

Adding apalutamide to ADT in the adjuvant and neoadjuvant settings improves outcomes in prostate cancer patients undergoing ...

With Men’s Health Week approaching, it is a good time to encourage open discussions about various health conditions, particularly prostate health. Driven by embarrassment, misconceptions, and a lack ...

Here is how robotic surgeries are paving way for new gen cancer treatment in the country - Read on to know all about it.

Wider resection of localized high-risk prostate cancer at surgery may come at the cost of sexual function and urinary incontinence. A phase 2 trial tested the merits of neoadjuvant therapy.

Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP) ...

Radical prostatectomy does not ensure a cure, with one in three men experiencing cancer recurrence and elevated PSA levels within 10 years post-surgery. Significant side effects of prostate removal ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...